<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>limited-stage SCLC &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/limited-stage-sclc/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 08 Sep 2025 09:50:44 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>limited-stage SCLC &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Phase III Trial Shows Hypofractionated Radiotherapy Plus Chemotherapy Matches Survival Rates and Reduces Toxicity Compared to Conventional Treatment in Limited-Stage SCLC</title>
		<link>https://bioengineer.org/phase-iii-trial-shows-hypofractionated-radiotherapy-plus-chemotherapy-matches-survival-rates-and-reduces-toxicity-compared-to-conventional-treatment-in-limited-stage-sclc/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 08 Sep 2025 09:50:40 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[chemoradiotherapy]]></category>
		<category><![CDATA[hypofractionated radiotherapy]]></category>
		<category><![CDATA[limited-stage SCLC]]></category>
		<category><![CDATA[phase III clinical trial]]></category>
		<category><![CDATA[toxicity reduction]]></category>
		<guid isPermaLink="false">https://bioengineer.org/phase-iii-trial-shows-hypofractionated-radiotherapy-plus-chemotherapy-matches-survival-rates-and-reduces-toxicity-compared-to-conventional-treatment-in-limited-stage-sclc/</guid>

					<description><![CDATA[(Barcelona, Spain — September 8, 2025) — A pivotal multi-center, randomized phase III clinical trial has recently demonstrated that a condensed, three-week hypofractionated radiotherapy regimen combined with concurrent chemotherapy yields survival outcomes comparable to the conventional six-week standard radiotherapy protocol in patients diagnosed with limited-stage small cell lung cancer (LS-SCLC). The findings, unveiled at the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">267468</post-id>	</item>
	</channel>
</rss>
